Volume 6 Supplement 2

Frontiers of Retrovirology: Complex retroviruses, retroelements and their hosts

Open Access

Study on the HIV drug resistance and its influencing factors in China

  • Wang Chongjian1, 4,
  • Li Yuqian2,
  • He Weihua3,
  • Zhang Xiaodong3,
  • Xu Yihua4 and
  • Nie Shaofa4
Retrovirology20096(Suppl 2):P94

DOI: 10.1186/1742-4690-6-S2-P94

Published: 24 September 2009

Objective

To investigate HIV drug resistance and its influencing factors, and then provide scientific evidence for antiretroviral therapy and reducing drug resistance.

Methods

Questionnaires and blood sample collection for drug resistance detection were conducted among 109 treated cases and 84 non-treated cases. Viral load was detected by NASBA and drug resistance was measured by nested PCR.

Results

The viral load of 95 cases (27 treated cases and 68 non-treated cases) was more than 1 000 copies/ml. The rate of drug resistance of treated and non-treated group was 40.74% and10.29% respectively (see Table 1). The rate of different drug resistance was higher significantly in treated group than in no-treated group. However, the sensitive of different drug resistance was lower significantly in treated group than in no-treated group (see Table 2). Therapy schedule of 17 treated cases was stopped due to a variety of reasons, such as death, dizziness, liver damage, bellyache, et al (see Table 3). Except for five death cases, two suicides were discovered at 16 and 42 days respectively after stopping therapy.
Table 1

The results of drug resistance detection in 95 cases with AIDS

Group

No.

Low-midrange resistance (%)

Height drug resistance (%)

Total of resistance (%)

Stopping therapy

12

0 (0.00)

3 (25.00)

3 (25.00)

Single therapy

11

0 (0.00)

6 (54.55)

6 (54.55)

Therapeutic alliance

4

0 (0.00)

2 (50.00)

2 (50.00)

No therapy

68

6 (8.82)

1 (1.47)

7 (10.29)

Table 2

The results of resistance detection of different drugs among 95 cases

    

Drug resistance

 

Group

Drug

No.

Sensitive (%)

Low resistance

Midrange resistance

Height resistance

Latent resistance

Total (%)

Therapy

DDI

27

19 (70.37)

1

1

6

0

8 (29.63)

 

D4T

27

24 (88.89)

2

1

0

0

3 (11.11)

 

EFV

27

15 (55.56)

0

1

9

2

12 (44.44)

 

NVP

27

16 (59.26)

0

0

10

1

11 (40.74)

No therapy

DDI

68

66 (97.06)

1

0

0

3

4 (5.88)

 

D4T

68

68 (100.00)

1

0

0

4

5 (7.35)

 

EFV

68

65 (95.58)

1

2

0

0

3 (4.41)

 

NVP

68

65 (95.58)

1

2

1

0

3 (4.41)

Table 3

The reasons of stopping therapy

Course of treatment (Months)

Death

Liver damage

Dizziness

Skin damage

Bellyache

Total (%)

0

1

1

3

-

-

5 (29.41)

1

2

2

1

1

1

7 (41.18)

2

2

-

1

-

-

3 (17.65)

      

7

 

1

 

1

 

2 (11.76)

Total (%)

5 (29.41)

4 (23.53)

5 (29.41)

2 (11.76)

1 (5.88)

17 (100)

Conclusion

Antiviral therapy can effectively reduce the viral load and inhibit viral replication. Drug resistance exists differently among treated and non-treated HIV/AIDS cases. HIV gene mutation may be the key reason for drug resistance.

Authors’ Affiliations

(1)
Department of Epidemiology and Biostatistics, School of Public Health, Zhengzhou University
(2)
Department of Clinical Pharmacology, School of Pharmaceutical Science, Zhengzhou University
(3)
Center for Disease Control and Prevention of Suizhou City
(4)
Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science &Technology

Copyright

© Chongjian et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd.

Advertisement